Encellin thin-film cell encapsulation (ENCRT / ENC-201)

What it is

Encellin is developing a thin, flexible, nanoporous thin-film pouch that holds insulin-producing cells and is implanted just under the skin — a strategy called Encapsulated Cell Replacement Therapy (ENCRT).¹ The membrane is engineered with pores small enough to keep the host's immune cells and antibodies out, but large enough to let glucose, oxygen, nutrients and insulin pass freely — so the cells can sense blood sugar and release insulin like a healthy islet would, in principle without lifelong immunosuppression.¹² The soft pouch is designed for subcutaneous implantation and retrieval.²

Where it came from

The technology was invented in Tejal Desai's lab at UC San Francisco and spun out by co-founder and CEO Crystal Nyitray.³ The foundational work showed that a thin-film device made from polycaprolactone (PCL) — a material already used in FDA-approved devices — could keep encapsulated insulin-secreting cells alive in mice for up to 90 days, triggering new blood-vessel growth around the device with little foreign-body reaction.³ A follow-up study used the nanoporous device to protect stem-cell-derived beta cells, showing engraftment and function out to 6 months in animals, immune isolation from the host, and — importantly for safety — prevention of stray stem cells escaping the device.⁴

The clinical evidence so far

The first-in-human study (NCT06408311, "ENC-201-CED") is a Phase 1 safety and tolerability trial in adults (18–70) with type 1 diabetes who receive donor (cadaveric) human islets sealed inside the device, run at the University Health Network in Toronto and McGill in Montreal — the only two sites, both in Canada; it began in 2024. The registry estimates 10 participants; the July 2026 sponsor/society report says enrollment finished at seven.⁵⁶ The trial is now active but no longer recruiting. The registry's estimated primary completion was 31 July 2026 — that date has passed, the last update is 11 March 2026, and no results are posted. Estimated study completion remains 30 October 2026. A passed primary-completion date is not a result.⁵ Its main goal is device-related safety, with explants examined for islet survival and fibrosis — not insulin independence.⁵ In January 2026 Encellin reported non-fibrotic, vascularized integration in explants from the first five subjects at four months; viable islets were identified in the initial evaluated explant.⁷ In a July 2026 ISSCR release, Encellin reported non-fibrotic engraftment across seven participants, host vascularization and transplanted islets identified in multiple participants. The full dataset remained under analysis.⁶ These are interim sponsor/society observations, not a peer-reviewed efficacy result. No human insulin-independence or C-peptide efficacy data have been reported, and whether the approach truly avoids the need for immunosuppression in people is still being tested.⁵⁷ In animal models, islets in the Encellin device reportedly reversed diabetes with no fibrosis or immune response.¹

Durability, eligibility and safety

Durability is the make-or-break question for all encapsulation: past capsules failed because scar tissue (pericapsular fibrotic overgrowth) walls them off and starves the cells of oxygen.⁸ Encellin's thin-film, vascularization-promoting design is aimed squarely at that failure mode, and the early human explant data are encouraging — but long-term function is unproven.⁷⁸ Current eligibility mirrors standard islet-infusion candidates; broad reach ultimately depends on moving from scarce donor islets to a renewable stem-cell-derived cell source, which the platform is designed to accommodate but has not yet tested clinically.⁵⁴ Subcutaneous placement permits retrieval, but comparative clinical safety against intraportal transplantation has not been established.²⁵

What's coming

Encellin raised $9.9M led by Khosla Ventures (Dec 2023) to carry the device through this Phase 1 trial.⁹ Near-term, a fuller safety readout is still the next thing to watch: estimated study completion is 30 October 2026. The estimated primary-completion date of 31 July 2026 has already passed without posted results, so do not treat the calendar as a readout.⁵ Longer-term, the company aims to pair the device with stem-cell-derived islets — the only way to make a cure scalable — and to extend the platform to other endocrine diseases.¹⁴ For now this is early-stage research: promising biology and a strong safety rationale, but no proof yet that it frees people from insulin.

References